Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study

Lin, Weihong; Cao, Dongyan; Shen, Keng

doi:10.2147/cmar.s186258

Cited by 19 publications

(9 citation statements)

References 34 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of our contrasting result, we confirmed the mucinous character of the UT-OV-1 by immunohistochemistry. The tumor cells were positive for CDX2, CEA, CK7 and p53, which are features of ovarian mucinous adenocarcinoma, intestinal type (42,43). This discrepancy might be due to the availability of better diagnostic tools which has led to improved histopathological diagnosis of different types of mucinous ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro

et al. 2020

View full text Add to dashboard Cite

Background/Aim: The combination of paclitaxel and carboplatin is the standard chemotherapy for ovarian cancer. Previous studies have implied that vitamin D (1,25-D3) may have growth inhibitory effects in ovarian cancer. This study aimed to investigate the effect of paclitaxel, carboplatin and 1,25-D3 on the growth of ovarian cancer cells in vitro, based on the hypothesis that 1,25-D3 might potentiate the effect of paclitaxel and/or carboplatin. Materials and Methods: Three non-commercial ovarian carcinoma cell lines UT-OV-1(mucinous), UT-OV-3B (serous) and UT-OV-4 (endometrioid) were exposed to different concentrations of 1,25-D3, paclitaxel and carboplatin, respectively. The cell viability was measured using a Crystal violet assay kit. The cellular vitamin D receptor (VDR) mRNA levels were measured by qRT-PCR using the LightCycler equipment. Results: The growth-inhibitory effect of the combination of paclitaxel and carboplatin was 56% in UT-OV-1, 33% in UT-OV-3B and 47% in UT-OV-4 cells. Single 1,25-D3 (10 μM) inhibited the growth of UT-OV-3B and UT-OV-4 by 23% and 28%, respectively, whereas no effect was seen in UT-OV-1 cells. These results are in line with the finding that the expression of VDR was high in UT-OV-3B and UT-OV-4, but very low in UT-OV-1. The combination of 1,25-D3, paclitaxel and carboplatin resulted in 61%, 46% and 58% growth reduction in UT-OV-1, UT-OV-3B and UT-OV-4 cells, respectively. The additive effect of 1,25-D3 was 21% in UT-OV-4, 20% in UT-OV-3B and 12% in UT-OV-1 cell line. Conclusion: The results imply that combining 1,25-D3 with paclitaxel and carboplatin may potentiate their growth inhibitory effect on ovarian cancer cells with high VDR expression.

show abstract

Section: Discussionmentioning

confidence: 99%

Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro

et al. 2020

View full text Add to dashboard Cite

show abstract

“…30 Some tumorassociated antigens have been measured in serum from patients with malignancy and were found to be related to the clinical course of disease. 31 Other malignancies closely related to gynecologic cancers have examined serum markers, [32][33][34][35] including SCC-Ag, AFP, CA153, CEA, CA125 and CA199 have been of great value for evaluation of pretreatment, treatment effect and for follow-up and establishment of patient prognoses. In our study, we collected clinicopathological data of the early stage ADC patients and analyzed the association of pre-operative serum tumor markers with prognostic value, in order to look for predictive risk factors.…”

Section: Discussionmentioning

confidence: 99%

<p>Combined Evaluation of Preoperative Serum CEA and CA125 as an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma</p>

Huang

Chen

et al. 2020

OTT

View full text Add to dashboard Cite

There is currently a lack of research on preoperative prognostic analysis of earlystage cervical adenocarcinoma (ADC). The purpose of our study was to clarify whether preoperative serum tumor-marker levels were of prognostic value in early-stage ADC. Patients and Methods: We performed a retrospective study of patients with International Federation of Gynecology and Obstetrics (FIGO) stage IA1-IIA1 and pathology-proven invasive ADC. We evaluated the relationship between preoperative serum tumor-marker levels and clinicopathological characteristics, and identified the relative preoperative risk factors affecting disease-free survival (DFS) and overall survival (OS). The optimal cutoff point of meaningful tumor markers was determined by the analysis of receiver operating characteristics (ROC), and the accuracy of the results was evaluated by the area under the curve (AUC). Results: Elevated carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCC-Ag), alpha-fetoprotein (AFP), carbohydrate antigen 153 (CA153) and carbohydrate antigen 199 (CA199) were associated with certain clinicopathologic features of early-stage ADC. The combination of elevated serum CEA and CA125 was significantly associated with FIGO stage, body mass index (BMI) and LNM. Kaplan-Meier survival curve and Cox regression analyses revealed that CEA and CA125 might have significant prognostic implications in early-stage ADC patients, and the combination of elevated serum CEA and CA125 served as an independent predictor of early-stage ADC. The optimal cutoff point of serum CA125 for prediction DFS and OS was 32.60 U/mL and of serum CEA were 2.85 ng/mL and 2.05 ng/mL, respectively. The AUC showed that serum CEA was a moderate predictor of OS. Conclusion: The preoperative serum levels of CEA and CA125 might have significant prognostic implications in early-stage ADC patients. Combined preoperative serum CEA and CA125 levels independently predicted the prognosis of early-stage ADC.

show abstract

“…Relevant studies have confirmed [ 15 ] that radical radiotherapy has the same effect as surgery. As a radiotherapy technique applied in the clinic for a long time, conformal radiotherapy can reduce the irradiation dose to the surrounding tissue by adjusting the morphology of the irradiated X-ray [ 16 , 18 , 19 ].…”

Section: Discussionmentioning

confidence: 96%

Efficacy of Modified Qingre Jiedu Decoction Combined with Three-Dimensional Conformal Radiotherapy in Treating Moderate to Advanced Ovarian Carcinoma and Its Effect on Levels of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 125

Ai¹,

Xie

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the efficacy of modified Qingre Jiedu decoction combined with three-dimensional conformal radiotherapy (3D-CRT) in treating moderate to advanced ovarian carcinoma (OC) and its effect on patients’ serum carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125). Methods. The clinical data of 84 patients with moderate to advanced OC treated in the gynecology department of Changqing District People’s Hospital of Jinan from February 2017 to February 2018 were selected for retrospective analysis, and the patients were divided into the single chemotherapy group (taxol + carboplatin, n = 42) and the combined group (modified Qingre Jiedu decoction+3D-CRT, n = 42) according to the parity of their admission numbers. By measuring their levels of serum CEA and CA125 after treatment, the cellular immune levels of the two groups were compared. Results. Compared with the single chemotherapy group after treatment, the combined group obtained significantly higher total clinical effective rate and 1-year, 2-year, and 3-year survival rates ( P < 0.05 ), significantly higher CD4+/CD8+ and NK cell level values ( P < 0.001 ), significantly lower serum CA125 and CEA level values ( P < 0.001 ), and significantly lower total incidence rates of toxic and side effects ( P < 0.05 ). Conclusion. The abovementioned results show that the combined treatment modality has a significant effect on prolonging the survival of patients with moderate to advanced OC and can effectively reduce the levels of tumor markers and improve the body’s immunity. Further study will be conducive to establishing a better solution for OC patients.

show abstract

Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study

Cited by 19 publications

References 34 publications

Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro

Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro

<p>Combined Evaluation of Preoperative Serum CEA and CA125 as an Independent Prognostic Biomarker in Patients with Early-Stage Cervical Adenocarcinoma</p>

Efficacy of Modified Qingre Jiedu Decoction Combined with Three-Dimensional Conformal Radiotherapy in Treating Moderate to Advanced Ovarian Carcinoma and Its Effect on Levels of Serum Carcinoembryonic Antigen and Carbohydrate Antigen 125

Contact Info

Product

Resources

About